Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Sodium Selenite Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Sodium Selenite: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Levonadifloxacin arginine salt Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Levonadifloxacin arginine salt: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Indacaterol Acetate/Mometasone Furoate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Indacaterol Acetate/Mometasone Furoate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Eugenol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Eugenol: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Trifarotene Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Trifarotene: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Sofpironium Bromide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Sofpironium Bromide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Nifurtimox Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Nifurtimox: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tafamidis Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Tafamidis: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Flumatinib Mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Flumatinib Mesylate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Somapacitan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Somapacitan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Emitasvir Phosphate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Emitasvir Phosphate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Laninamivir Octanoate Hydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Laninamivir Octanoate Hydrate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.